Aiming to transform cancer care by developing curative allogeneic cell therapies
PRESS RELEASES + EVENTS view all
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
– Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway –…
Century Therapeutics to Present at the AACR Annual Meeting 2023
PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology…
We are building a fully integrated biotechnology company that is developing transformational next generation iPSC-derived iNK and iT cell therapies for hematological and solid tumor malignancies.
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.